10 results on '"Raffoul, Wassim"'
Search Results
2. Human platelet lysate as a potential clinical-translatable supplement to support the neurotrophic properties of human adipose-derived stem cells
- Author
-
Palombella, Silvia, Guiotto, Martino, Higgins, Gillian C., Applegate, Laurent L., Raffoul, Wassim, Cherubino, Mario, Hart, Andrew, Riehle, Mathis O., and di Summa, Pietro G.
- Published
- 2020
- Full Text
- View/download PDF
3. Autologous and Allogeneic Cytotherapies for Large Knee (Osteo)Chondral Defects: Manufacturing Process Benchmarking and Parallel Functional Qualification.
- Author
-
Philippe, Virginie, Jeannerat, Annick, Peneveyre, Cédric, Jaccoud, Sandra, Scaletta, Corinne, Hirt-Burri, Nathalie, Abdel-Sayed, Philippe, Raffoul, Wassim, Darwiche, Salim, Applegate, Lee Ann, Martin, Robin, and Laurent, Alexis
- Subjects
MANUFACTURING defects ,MANUFACTURING processes ,CARTILAGE regeneration ,PARALLEL processing ,CELLULAR aging ,CELL transplantation ,KNEE ,ENDOCHONDRAL ossification - Abstract
Cytotherapies are often necessary for the management of symptomatic large knee (osteo)-chondral defects. While autologous chondrocyte implantation (ACI) has been clinically used for 30 years, allogeneic cells (clinical-grade FE002 primary chondroprogenitors) have been investigated in translational settings (Swiss progenitor cell transplantation program). The aim of this study was to comparatively assess autologous and allogeneic approaches (quality, safety, functional attributes) to cell-based knee chondrotherapies developed for clinical use. Protocol benchmarking from a manufacturing process and control viewpoint enabled us to highlight the respective advantages and risks. Safety data (telomerase and soft agarose colony formation assays, high passage cell senescence) and risk analyses were reported for the allogeneic FE002 cellular active substance in preparation for an autologous to allogeneic clinical protocol transposition. Validation results on autologous bioengineered grafts (autologous chondrocyte-bearing Chondro-Gide scaffolds) confirmed significant chondrogenic induction (COL2 and ACAN upregulation, extracellular matrix synthesis) after 2 weeks of co-culture. Allogeneic grafts (bearing FE002 primary chondroprogenitors) displayed comparable endpoint quality and functionality attributes. Parameters of translational relevance (transport medium, finished product suturability) were validated for the allogeneic protocol. Notably, the process-based benchmarking of both approaches highlighted the key advantages of allogeneic FE002 cell-bearing grafts (reduced cellular variability, enhanced process standardization, rationalized logistical and clinical pathways). Overall, this study built on our robust knowledge and local experience with ACI (long-term safety and efficacy), setting an appropriate standard for further clinical investigations into allogeneic progenitor cell-based orthopedic protocols. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Thermo-Responsive Hyaluronan-Based Hydrogels Combined with Allogeneic Cytotherapeutics for the Treatment of Osteoarthritis.
- Author
-
Porcello, Alexandre, Gonzalez-Fernandez, Paula, Jeannerat, Annick, Peneveyre, Cédric, Abdel-Sayed, Philippe, Scaletta, Corinne, Raffoul, Wassim, Hirt-Burri, Nathalie, Applegate, Lee Ann, Allémann, Eric, Laurent, Alexis, and Jordan, Olivier
- Subjects
HYDROGELS ,HYALURONIC acid ,OSTEOARTHRITIS ,RHEOLOGY (Biology) ,RHEOLOGY ,TRIBOLOGY - Abstract
Thermo-responsive hyaluronan-based hydrogels and FE002 human primary chondroprogenitor cell sources have both been previously proposed as modern therapeutic options for the management of osteoarthritis (OA). For the translational development of a potential orthopedic combination product based on both technologies, respective technical aspects required further optimization phases (e.g., hydrogel synthesis upscaling and sterilization, FE002 cytotherapeutic material stabilization). The first aim of the present study was to perform multi-step in vitro characterization of several combination product formulas throughout the established and the optimized manufacturing workflows, with a strong focus set on critical functional parameters. The second aim of the present study was to assess the applicability and the efficacy of the considered combination product prototypes in a rodent model of knee OA. Specific characterization results (i.e., spectral analysis, rheology, tribology, injectability, degradation assays, in vitro biocompatibility) of hyaluronan-based hydrogels modified with sulfo-dibenzocyclooctyne-PEG4-amine linkers and poly(N-isopropylacrylamide) (HA-L-PNIPAM) containing lyophilized FE002 human chondroprogenitors confirmed the suitability of the considered combination product components. Specifically, significantly enhanced resistance toward oxidative and enzymatic degradation was shown in vitro for the studied injectable combination product prototypes. Furthermore, extensive multi-parametric (i.e., tomography, histology, scoring) in vivo investigation of the effects of FE002 cell-laden HA-L-PNIPAM hydrogels in a rodent model revealed no general or local iatrogenic adverse effects, whereas it did reveal some beneficial trends against the development of knee OA. Overall, the present study addressed key aspects of the preclinical development process for novel biologically-based orthopedic combination products and shall serve as a robust methodological basis for further translational investigation and clinical work. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Back to the Cradle of Cytotherapy: Integrating a Century of Clinical Research and Biotechnology-Based Manufacturing for Modern Tissue-Specific Cellular Treatments in Switzerland.
- Author
-
Laurent, Alexis, Abdel-Sayed, Philippe, Scaletta, Corinne, Laurent, Philippe, Laurent, Elénie, Michetti, Murielle, de Buys Roessingh, Anthony, Raffoul, Wassim, Hirt-Burri, Nathalie, and Applegate, Lee Ann
- Subjects
MEDICAL research ,CELL transplantation ,CELLULAR therapy ,REGENERATIVE medicine ,PROGENITOR cells - Abstract
Empirically studied by Dr. Brown-Séquard in the late 1800s, cytotherapies were later democratized by Dr. Niehans during the twentieth century in Western Switzerland. Many local cultural landmarks around the Léman Riviera are reminiscent of the inception of such cell-based treatments. Despite the discreet extravagance of the remaining heirs of "living cell therapy" and specific enforcements by Swiss health authorities, current interest in modern and scientifically sound cell-based regenerative medicine has never been stronger. Respective progress made in bioengineering and in biotechnology have enabled the clinical implementation of modern cell-based therapeutic treatments within updated medical and regulatory frameworks. Notably, the Swiss progenitor cell transplantation program has enabled the gathering of two decades of clinical experience in Lausanne for the therapeutic management of cutaneous and musculoskeletal affections, using homologous allogeneic cell-based approaches. While striking conceptual similarities exist between the respective works of the fathers of cytotherapy and of modern highly specialized clinicians, major and important iterative updates have been implemented, centered on product quality and risk-analysis-based patient safety insurance. This perspective article highlights some historical similarities and major evolutive differences, particularly regarding product safety and quality issues, characterizing the use of cell-based therapies in Switzerland over the past century. We outline the vast therapeutic potential to be harnessed for the benefit of overall patient health and the importance of specific scientific methodological aspects. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Burn Center Organization and Cellular Therapy Integration: Managing Risks and Costs.
- Author
-
Chemali, Michèle, Laurent, Alexis, Scaletta, Corinne, Waselle, Laurent, Simon, Jeanne-Pascale, Michetti, Murielle, Brunet, Jean-François, Flahaut, Marjorie, Hirt-Burri, Nathalie, Raffoul, Wassim, Applegate, Lee Ann, Roessingh, Anthony S de Buys, Abdel-Sayed, Philippe, and de Buys Roessingh, Anthony S
- Subjects
BURN care units ,CELLULAR therapy ,ARTIFICIAL respiration ,INTENSIVE care units ,CHEMICAL burns ,MEDICAL care ,HOSPITAL admission & discharge ,PATIENTS - Abstract
The complex management of severe burn victims requires an integrative collaboration of multidisciplinary specialists in order to ensure quality and excellence in healthcare. This multidisciplinary care has quickly led to the integration of cell therapies in clinical care of burn patients. Specific advances in cellular therapy together with medical care have allowed for rapid treatment, shorter residence in hospitals and intensive care units, shorter durations of mechanical ventilation, lower complications and surgery interventions, and decreasing mortality rates. However, naturally fluctuating patient admission rates increase pressure toward optimized resource utilization. Besides, European translational developments of cellular therapies currently face potentially jeopardizing challenges on the policy front. The aim of the present work is to provide key considerations in burn care with focus on architectural and organizational aspects of burn centers, management of cellular therapy products, and guidelines in evolving restrictive regulations relative to standardized cell therapies. Thus, based on our experience, we present herein integrated management of risks and costs for preserving and optimizing clinical care and cellular therapies for patients in dire need. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Efficient decellularization of equine tendon with preserved biomechanical properties and cytocompatibility for human tendon surgery indications.
- Author
-
Aeberhard, Pierre‐Arnaud, Grognuz, Anthony, Peneveyre, Cédric, McCallin, Shawna, Hirt‐Burri, Nathalie, Antons, Jens, Pioletti, Dominique, Raffoul, Wassim, and Applegate, Lee Ann
- Subjects
FLEXOR tendons ,TENDONS ,YOUNG'S modulus ,TENDON injuries ,CELLULAR therapy ,PROGENITOR cells ,CYTOCOMPATIBILITY - Abstract
Chronic and acute tendon injuries are frequent afflictions, for which treatment is often long and unsatisfactory. When facing extended injuries, matrices and scaffolds with sufficient biomechanical properties are required for surgical repair and could additionally serve as supports for cellular therapies to improve healing. In this study, protocols of either commonly used detergents only (SDS 1%, Triton 1%, TBP 1%, and Tween‐20 1%) or a combination of freeze/thaw (F/T) cycles with decellularization agents (NaCl 1M, ddH2O) were evaluated for the decellularization of horse equine superficial digital flexor tendon (SDFT) for hand flexor or extensor tendon reconstruction. Decellularization efficiency was assessed microscopically by histological staining (HE, DAPI) and DNA quantification. Macroscopical structure and biomechanical integrity of the tendon matrices were further assessed by gross observation, histological staining (SR), and mechanical testing (ultimate strain and stress, Young's modulus, energy to failure) for select protocols. Decellularization with hypertonic NaCl 1M in association with F/T cycles produced the most robust tendon matrices, which were nontoxic after 10 days for subsequent recellularization with human fetal progenitor tendon cells (hFPTs). This standardized protocol uses a less aggressive decellularization agent than current practice, which allows subsequent reseeding with allogenic cells, therefore making them very suitable and bioengineered tendon matrices for human tendon reconstruction in the clinic. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine.
- Author
-
Laurent, Alexis, Abdel-Sayed, Philippe, Hirt-Burri, Nathalie, Scaletta, Corinne, Michetti, Murielle, de Buys Roessingh, Anthony, Raffoul, Wassim, and Applegate, Lee Ann
- Subjects
REGENERATIVE medicine ,PROGENITOR cells ,LUNGS ,COVID-19 ,CURRENT good manufacturing practices ,VACCINE trials - Abstract
The objective of this review is to describe the evolution of lung tissue-derived diploid progenitor cell applications, ranging from historical biotechnological substrate functions for vaccine production and testing to current investigations around potential therapeutic use in respiratory tract regenerative medicine. Such cell types (e.g., MRC-5 or WI-38 sources) were extensively studied since the 1960s and have been continuously used over five decades as safe and sustainable industrial vaccine substrates. Recent research and development efforts around diploid progenitor lung cells (e.g., FE002-Lu or Walvax-2 sources) consist in qualification for potential use as optimal and renewed vaccine production substrates and, alternatively, for potential therapeutic applications in respiratory tract regenerative medicine. Potentially effective, safe, and sustainable cell therapy approaches for the management of inflammatory lung diseases or affections and related symptoms (e.g., COVID-19 patients and burn patient severe inhalation syndrome) using local homologous allogeneic cell-based or cell-derived product administrations are considered. Overall, lung tissue-derived progenitor cells isolated and produced under good manufacturing practices (GMP) may be used with high versatility. They can either act as key industrial platforms optimally conforming to specific pharmacopoeial requirements or as active pharmaceutical ingredients (API) for potentially effective promotion of lung tissue repair or regeneration. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Antimicrobial Peptide Dendrimers and Quorum-Sensing Inhibitors in Formulating Next-Generation Anti-Infection Cell Therapy Dressings for Burns.
- Author
-
Jafari, Paris, Luscher, Alexandre, Siriwardena, Thissa, Michetti, Murielle, Que, Yok-Ai, Rahme, Laurence G., Reymond, Jean-Louis, Raffoul, Wassim, Van Delden, Christian, Applegate, Lee Ann, and Köhler, Thilo
- Subjects
CELLULAR therapy ,QUORUM sensing ,PROGENITOR cells ,MULTIDRUG resistance ,BIOTHERAPY ,BACTERIAL growth ,DENDRIMERS ,ANTIBIOTICS - Abstract
Multidrug resistance infections are the main cause of failure in the pro-regenerative cell-mediated therapy of burn wounds. The collagen-based matrices for delivery of cells could be potential substrates to support bacterial growth and subsequent lysis of the collagen leading to a cell therapy loss. In this article, we report the development of a new generation of cell therapy formulations with the capacity to resist infections through the bactericidal effect of antimicrobial peptide dendrimers and the anti-virulence effect of anti-quorum sensing MvfR (PqsR) system compounds, which are incorporated into their formulation. Anti-quorum sensing compounds limit the pathogenicity and antibiotic tolerance of pathogenic bacteria involved in the burn wound infections, by inhibiting their virulence pathways. For the first time, we report a biological cell therapy dressing incorporating live progenitor cells, antimicrobial peptide dendrimers, and anti-MvfR compounds, which exhibit bactericidal and anti-virulence properties without compromising the viability of the progenitor cells. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Biologicals and fetal cell therapy for wound healing and scar management
- Author
-
Hirt-Burri, Nathalie, Ramelet, Albert-Adrien, Raffoul, Wassim, De Buys Roessingh, Anthony, Scaletta, Corinne, Pioletti, Dominique P., and Laurent-Applegate, Lee Ann
- Subjects
chronic ulcers ,scars ,wound healing ,cell therapy - Abstract
Few biopharmaceutical preparations developed from biologicals are available for tissue regeneration and scar management. When developing biological treatments with cellular therapy, selection of cell types and establishment of consistent cell banks are crucial steps in whole-cell bioprocessing. Various cell types have been used in treatment of wounds to reduce scar to date including autolog and allogenic skin cells, platelets, placenta and amniotic extracts. Experience with fetal cells show that they may provide an interesting cell choice due to facility of out-scaling and known properties for wound healing without scar. Differential gene profiling has helped to point to potential indicators of repair which include cell adhesion, extracellular matrix, cytokines, growth factors and development. Safety has been evidenced in Phase I & II clinical fetal cell use for burn and wound treatments with different cell delivery systems. Overall fetal cells present technical and therapeutic advantages compared to other cell types for effective cell-based therapy for wound and scar management.
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.